TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28372313

Group type: EXPERIMENTAL
Intervention: 3‐point bending cervical extension traction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretching exercises and infrared
Number of subjects: 30
Study: 25643766

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil combination
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil combination
Number of subjects: 66

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 66
Study: 23258191

Group type: EXPERIMENTAL
Intervention: Individually tailored physical and daily activities
Number of subjects: 322

Group type: COMPARATOR
Intervention: Ordinary care
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Individually tailored physical and daily activities (more than 150 min/week)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Individually tailored physical and daily activities (more than 10 weeks)
Number of subjects: 322
Study: 22006695

Group type: EXPERIMENTAL
Intervention: Sitting body orientation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Supine body orientation
Number of subjects: 21
Study: 19143854

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily (SOL5)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily (SOL10)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Tolterodine immediate release 2 mg twice daily (TOL4)
Number of subjects: 357
Study: 17046466

Group type: EXPERIMENTAL
Intervention: 6-thioguanine
Number of subjects: 1498

Group type: COMPARATOR
Intervention: 6-mercaptopurine
Number of subjects: 1498
Study: 15631608

Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day for 10 weeks)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 11762658

Group type: EXPERIMENTAL
Intervention: Desogestrel 75 microg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Copper-bearing IUCD
Number of subjects: 83
Study: 10322871

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BYHWD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 60
Study: 7970999

Group type: EXPERIMENTAL
Intervention: Desmopressin 400 micrograms
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3679623

Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29871368

Group type: EXPERIMENTAL
Intervention: 4 mL ESI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 mL ESI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mL ESI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (4 mL, 6 mL, 8 mL)
Number of subjects: 60
Study: 29071947

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation of the sciatic nerve trunk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple routine acupuncture (Control)
Number of subjects: 60
Study: 24846036

Group type: EXPERIMENTAL
Intervention: Active treatment (education and advice, manual therapy, home exercise, gait aid if appropriate)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham treatment (inactive ultrasound and inert gel)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 102
Study: 22551785

Group type: EXPERIMENTAL
Intervention: Sorafenib 600 mg b.i.d.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sorafenib (dose-escalated to 600 mg b.i.d. and 800 mg b.i.d.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sorafenib (dose-escalated)
Number of subjects: 44
Study: 19448128

Group type: EXPERIMENTAL
Intervention: NIDCAP (Newborn Individualized Developmental Care and Assessment Program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 18798437

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg) and clindamycin (100 mg) in vaginal tablets
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clindamycin alone (600 mg/daily) orally for six days
Number of subjects: 105
Study: 15860388

Group type: EXPERIMENTAL
Intervention: Supervised cycle ergometer exercise training (ET) at 60% of peak VO2, three times a week, 60 min each session, for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not exercised)
Number of subjects: 59
Study: 12504698

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 269

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 269
Study: 10929164

Group type: EXPERIMENTAL
Intervention: Multidimensional preoperative intervention including exercise training twice per week, education and reinforcement, and monthly nurse-initiated telephone calls.
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (no preoperative intervention).
Number of subjects: 249
Study: 8694317

Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 micrograms/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 micrograms/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: alfentanil 10 micrograms/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: alfentanil 20 micrograms/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 1563371

Group type: EXPERIMENTAL
Intervention: Cycling at 80 W for 12 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive sitting (control)
Number of subjects: 10
Study: 3781322

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg iv
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal gastric emptying
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 28726273

Group type: EXPERIMENTAL
Intervention: NIF+EGCG
Number of subjects: 350

Group type: COMPARATOR
Intervention: NIF+placebo
Number of subjects: 350
Study: 26947059

Group type: EXPERIMENTAL
Intervention: Supervised-facility multicomponent exercise program (MEP), 65 minutes, 5 days/week, for 24 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Supervised-facility multicomponent exercise program (MEP)
Number of subjects: 100
Study: 24014042

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for anorexia nervosa (CBT-AN)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management
Number of subjects: 63
Study: 21510830

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + Aliskiren 300 mg
Number of subjects: 120
Study: 19723313

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) by a specialised physiotherapist for 9-18 sessions over 6 months
Number of subjects: 400

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT) surgery
Number of subjects: 400
Study: 17717214

Group type: EXPERIMENTAL
Intervention: Group I: ETT positioned by auscultation and withdrawn 2 cm
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group II: ETT positioned with prescribed marks at vocal cords
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group III: ETT positioned by palpating tip at suprasternal notch
Number of subjects: 107
Study: 15065835

Group type: EXPERIMENTAL
Intervention: Resistive inspiratory manoeuvres (RIM) at 80% of maximum sustained inspiratory pressure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standardised physiotherapy (SP) for 30 min
Number of subjects: 20
Study: 11481401

Group type: EXPERIMENTAL
Intervention: apoLFbuf (4.5 g bovine LF with gastric pH buffer)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: apoLF (4.5 g bovine LF without buffer)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: holoLF (iron-saturated LF)
Number of subjects: 12
Study: 9669008

Group type: EXPERIMENTAL
Intervention: bupivacaine-fentanyl (0.125% bupivacaine with 0.005 mg/ml fentanyl)
Number of subjects: 30

Group type: COMPARATOR
Intervention: bupivacaine-morphine (0.125% bupivacaine with 0.05 mg/ml morphine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bupivacaine-fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: bupivacaine-morphine
Number of subjects: 30
Study: 7508689

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not treated with hydroxyurea)
Number of subjects: 0
Study: 3175546

Group type: EXPERIMENTAL
Intervention: Packages containing suppositories
Number of subjects: 94

Group type: COMPARATOR
Intervention: Packages containing capsules or tablets
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Six different packages for suppositories
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Evaluation of six packages by patients
Number of subjects: 94
Study: 31188691

Group type: EXPERIMENTAL
Intervention: Bench Press (BP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Half Squat (HS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bench Press plus Half Squat (BP plus HS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 15
Study: 28363686

Group type: EXPERIMENTAL
Intervention: Clinical pathways-based intervention
Number of subjects: 15141

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 15141
Study: 25166623

Group type: EXPERIMENTAL
Intervention: Routine evaluation of gastric residuals (RGR) prior to feeds
Number of subjects: 61

Group type: COMPARATOR
Intervention: No routine evaluation of gastric residuals (Control)
Number of subjects: 61
Study: 23145973

Group type: EXPERIMENTAL
Intervention: High fluoride (≥2 ppm) and heavy force (225 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low fluoride (≤0.05 ppm) and heavy force (225 g)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High fluoride (≥2 ppm) and light force (25 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low fluoride (≤0.05 ppm) and light force (25 g)
Number of subjects: 48
Study: 20847092

Group type: EXPERIMENTAL
Intervention: Daily administration of maintenance prednisolone for 7 days during intercurrent infections
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alternate-day prednisolone
Number of subjects: 100
Study: 19650876

Group type: EXPERIMENTAL
Intervention: Insulin detemir (660 mU/kg, infusion rate 5 mU/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Human insulin (60 mU/kg, infusion rate 2 mU/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 12

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin detemir and Human insulin
Number of subjects: 12
Study: 21444871

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin chemoradiotherapy followed by brachytherapy and adjuvant gemcitabine/cisplatin chemotherapy
Number of subjects: 515

Group type: COMPARATOR
Intervention: Cisplatin and concurrent XRT followed by BCT only
Number of subjects: 515
Study: 16054887

Group type: EXPERIMENTAL
Intervention: HD-HSA (Human serum albumin from hemodialysis patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal-HSA (Human serum albumin from healthy subjects)
Number of subjects: 20
Study: 12406842

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 14
Study: 9620099

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g every 6 hours
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg by intravenous bolus every 8 hours
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cimetidine 900 mg by continuous intravenous infusion/24 hours
Number of subjects: 53
Study: 7609574

Group type: EXPERIMENTAL
Intervention: Interleukin-8
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant factor
Number of subjects: 12
Study: 2693929

Group type: EXPERIMENTAL
Intervention: Letosteine (25 mg x 3 g/die for 10 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 348546

Group type: EXPERIMENTAL
Intervention: Nifedipine (N) 10 mg, oral
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: N + isosorbide dinitrate (ISDN) 10 mg oral
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: N + propranolol (Pr) 40 mg, oral
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg oral
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31474462

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS) using a silicone pacifier 120 seconds before, during, and 120 seconds after heel prick
Number of subjects: 42
Study: 29499289

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection + 12 weeks of exercise therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo injection + 12 weeks of exercise therapy
Number of subjects: 50
Study: 27991432

Group type: EXPERIMENTAL
Intervention: omeprazole/esomeprazole (strong CYP2C19 inhibitors)
Number of subjects: 54

Group type: COMPARATOR
Intervention: pantoprazole/rabeprazole (weak CYP2C19 inhibitors)
Number of subjects: 54
Study: 24809838

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 54
Study: 24041307

Group type: EXPERIMENTAL
Intervention: D7N mutation of Aβ40 and Aβ42 peptides
Number of subjects: 0
Study: 19933908

Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg by mouth daily) with carboplatin (6 mg/mL x min) and paclitaxel (200 mg/m2 on day 3)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo with carboplatin (6 mg/mL x min) and paclitaxel (200 mg/m2 on day 3)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg by mouth daily) with carboplatin and paclitaxel
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo with carboplatin and paclitaxel
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg by mouth daily)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 18403184

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (MRS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (N=48)
Number of subjects: 36
Study: 16153271

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) 5 microg/mL infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 16
Study: 12514672

Group type: EXPERIMENTAL
Intervention: Conivaptan (vasopressin antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10962771

Group type: EXPERIMENTAL
Intervention: Daily maintenance doses every 24 hours (4 or 8 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Double the daily maintenance dose every 48 hours (8 or 16 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quadruple the daily maintenance dose every 96 hours (16 or 32 mg/70 kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Daily dosing regimen
Number of subjects: 14
Study: 8553952

Group type: EXPERIMENTAL
Intervention: i.v. administration of ultrasmall superparamagnetic iron oxide (USPIO) particle (Code 7227)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fat-suppressed T1-weighted imaging
Number of subjects: 27
Study: 1985710

Group type: EXPERIMENTAL
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion at 300 mg/m2/d for 10 weeks of every 12 weeks
Number of subjects: 184

Group type: COMPARATOR
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion with weekly cisplatin (20 mg/m2)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion
Number of subjects: 184

Group type: COMPARATOR
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion with weekly cisplatin
Number of subjects: 184
Study: 7104464

Group type: EXPERIMENTAL
Intervention: Lipid diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fasting diet
Number of subjects: 5

Group type: COMPARATOR
Intervention: Carbohydrate diet
Number of subjects: 5
Study: 31599775

Group type: EXPERIMENTAL
Intervention: High-density spectral domain optical coherence tomography (SD-OCT) optic nerve volume scans
Number of subjects: 256
Study: 30203752

Group type: EXPERIMENTAL
Intervention: Cervical paravertebral nerve block combined with Mailuoning and Angelica sinensis injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Glucocorticoid nerve block therapy
Number of subjects: 120
Study: 26786823

Group type: COMPARATOR
Intervention: Handling money (market-mode cue)
Number of subjects: 0
Study: 23807029

Group type: EXPERIMENTAL
Intervention: Stabilizing knee brace for 6 weeks post-operatively
Number of subjects: 64

Group type: COMPARATOR
Intervention: No stabilizing knee brace for 6 weeks post-operatively
Number of subjects: 64
Study: 23062767

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg + Ezetimibe 10/10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normolipidemic patients)
Number of subjects: 60
Study: 19181399

Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) assessment
Number of subjects: 321
Study: 18572078

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg per day
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3 mg per day
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 16095532

Group type: EXPERIMENTAL
Intervention: Algorithm for identifying and separating beats from arterial pulse records
Number of subjects: 800

Group type: COMPARATOR
Intervention: Human operators
Number of subjects: 800
Study: 12415583

Group type: EXPERIMENTAL
Intervention: Adalimumab 0.5 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adalimumab 1 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adalimumab 3 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adalimumab 5 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adalimumab 10 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12802246

Group type: EXPERIMENTAL
Intervention: Portable voice organizer
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intervention (unrecorded goals)
Number of subjects: 10
Study: 9836028

Group type: EXPERIMENTAL
Intervention: Diltiazem-lidocaine combination (0.3 mg.kg‐1 diltiazem plus 1.5 mg.kg‐1 lidocaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diltiazem (0.3 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg.kg‐1)
Number of subjects: 60
Study: 7661296

Group type: EXPERIMENTAL
Intervention: Local continuous microwave therapy (CM)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo treatment (controls)
Number of subjects: 141
Study: 2758362

Group type: EXPERIMENTAL
Intervention: Very low ingestion of hens' egg and cows' milk
Number of subjects: 162

Group type: COMPARATOR
Intervention: Daily ingestion of one hens' egg and about 11 of cows' milk
Number of subjects: 162
Study: 345735

Group type: EXPERIMENTAL
Intervention: 1.5% timolol maleate administered twice a day for two weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine hydrochloride (control)
Number of subjects: 0
Study: 31012238

Group type: EXPERIMENTAL
Intervention: Unsupervised home-based exergaming for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 27874292

Group type: EXPERIMENTAL
Intervention: G‐CSF infusion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (opted out of G‐CSF)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 26161609

Group type: EXPERIMENTAL
Intervention: Gaseous Ozone (GO) + Fuji Triage Fissure Sealant (FS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gaseous Ozone (GO) + Aegis Fissure Sealant (FS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gaseous Ozone (GO) + Helioseal Fissure Sealant (FS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fuji Triage Fissure Sealant (FS) without Gaseous Ozone (Control)
Number of subjects: 60
Study: 23289762

Group type: COMPARATOR
Intervention: Levamisole film-coated tablets
Number of subjects: 100
Study: 21041041

Group type: EXPERIMENTAL
Intervention: Telephone continuing care with voucher incentives
Number of subjects: 195

Group type: COMPARATOR
Intervention: Telephone continuing care without voucher incentives
Number of subjects: 195
Study: 19051275

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Rational emotive behavioral therapy (REBT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fluoxetine (Prozac)
Number of subjects: 170
Study: 17849636

Group type: EXPERIMENTAL
Intervention: Protocol A (electroacoustic analysis, real-ear measures, hearing aid adjustments based on users' comments)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Protocol B (Protocol A + speech-in-noise test, loudness discomfort levels, aided loudness)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 32

Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 32
Study: 15115421

Group type: EXPERIMENTAL
Intervention: Graded exercise with pacing
Number of subjects: 61

Group type: COMPARATOR
Intervention: Relaxation/flexibility therapy
Number of subjects: 61
Study: 11293460

Group type: EXPERIMENTAL
Intervention: Strategy adaptivity in response to success and failure feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reasoning ability and working‐memory capacity
Number of subjects: 0
Study: 9409351

Group type: EXPERIMENTAL
Intervention: Clozapine (12.5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Clozapine (average daily dose of 45 +/- 9.6 mg for 15.5 +/- 8.3 months)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8126300

Group type: EXPERIMENTAL
Intervention: Nitrous oxide and behavioral management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral management
Number of subjects: 0
Study: 2960579

Group type: EXPERIMENTAL
Intervention: Oral-motor treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Behavior modification
Number of subjects: 5
Study: 31985859

Group type: EXPERIMENTAL
Intervention: Living Together With Dementia training programme
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27